← Eichor
Condition: Phase 2 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Phase 2

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04332874Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Im
Phase 2 · 1 location(s) · Diwakar Davar · NCT06499896Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 8 location(s) · Ming-Yu Lien · NCT07039162Suvorexant for Treatment of AUD and PTSD
Phase 2 · 2 location(s) · Pharmacotherapies for Alcohol and Substance Use Disorders Al · NCT06679062Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer
Phase 2 · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06938724Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06369259Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Phase 2 · 22 location(s) · Medical University of Vienna · NCT01356290Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
Phase 2 · 2 location(s) · Jair Bar, M.D., Ph.D. · NCT06206850Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · BeBetter Med Inc · NCT06706713TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinom
Phase 2 · 14 location(s) · Centre Francois Baclesse · NCT04678362A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and
Phase 2 · 78 location(s) · Apellis Pharmaceuticals, Inc. · NCT07215390A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT04501523Pelvic Cancer Registry for Online Adapted Radiotherapy
Phase N/A · 1 location(s) · University Medical Center Goettingen · NCT06185062First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Phase 2 · 1 location(s) · Xiaorong Dong · NCT05745350Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Phase 2 · 1 location(s) · Fox Chase Cancer Center · NCT05800574Evaluation of BTV100 in Subjects With Dry Eye Disease
Phase 2 · 6 location(s) · BioTheraVision, Inc. · NCT06543303A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Phase 1 · 6 location(s) · Janssen Research & Development, LLC · NCT07082920Teclistamab in Previously Treated AL Amyloidosis
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06935162Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 2 · 20 location(s) · Takeda · NCT06798012Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT05271292Toripalimab Combined With CAV/IE Regimen
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT04589741Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients Wi
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04240054Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear
Phase 2 · 3 location(s) · Tego Science, Inc. · NCT07219654Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Phase 2 · 1 location(s) · BC Centre on Substance Use · NCT05985850Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04645160Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Phase 2 · 1 location(s) · Cedars-Sinai Medical Center · NCT03774446Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
Phase 2 · 1 location(s) · Research Institute of Geroprotective Technologies · NCT07397351
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.